Compare Gilead Sciences, Inc. (GILD) vs Nomura Holdings Inc (NMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nomura Holdings Inc — how do they compare? Gilead Sciences, Inc. trades at $135.73 (market cap $168.35B), while Nomura Holdings Inc trades at $9.93 (market cap $28.46B). The key difference: Gilead Sciences, Inc. is far larger — about 5.9× Nomura Holdings Inc's market cap, and Nomura Holdings Inc pays the higher dividend (3.31%). Which is the better fit depends on your goals.
| GILD | NMR | |
|---|---|---|
Market Cap | $168.35B | $28.46B |
Sector | Health | Financials |
52-Week High | $155.80 | $10.04 |
52-Week Low | $110.56 | $6.73 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Nomura Holdings (NMR) trades at $9.905, up 0.87% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamentals, including a P/E of 11.59, net income margin of 20.4%, and robust revenue growth to $1.66 trillion in 2025. Recent Q2 2026 earnings beat expectations, and news highlights momentum in wholesale and wealth management divisions.
Outlook remains positive due to earnings strength and undervaluation, but risks include volatile cash flows and rising debt-to-asset ratio. Analyst consensus is mixed with 33% buy ratings, suggesting cautious optimism amid operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nomura Holdings Inc
Nomura is Japan's largest broker, about twice the size of rival Daiwa Securities and roughly three times the size of the securities units of the three megabanks. It is also the largest asset-management company in Japan, with a similar size differential compared with its rivals. Despite its topnotch brand name in retail broking and asset management in Japan, Nomura has struggled to compete effectively in the institutional securities business against larger global rivals. In 2008, Nomura bought European and Asian assets of the failed Lehman Brothers, which led to a sharply higher cost base but did not provide commensurate revenue. Nomura has reduced the scale of these businesses but maintains its ambition to compete globally with the top players.
Read more on NMR →
